Fidelity Advisor Biotechnology Cl C
Fidelity Advisor Biotechnology Cl C (FBTCX)
FBTCX is a mutual fund offered by Fidelity Advisor that focuses on investing in biotechnology companies. It is classified as a Class C fund, meaning it has a lower initial investment requirement and may have higher fees compared to other classes. This fund aims to provide investors with exposure to the rapidly growing biotechnology industry, which includes companies involved in the development and commercialization of innovative medical treatments and technologies. With a diverse portfolio of biotech stocks, FBTCX offers potential for long-term growth and may be suitable for investors seeking higher risk and potential returns.
FBTCX Mutual Fund Chart & Stats
- Previous Close
- $36.63
- Sub-Category
- Sector-Specific
- Total Liabilities
- $56.19M
- Expense Ratio
- 1.69%
- Holding Count
- 78
- Brand
- Fidelity Advisor Series Vii
- Category
- Equity
- Total Assets
- 2.26B
- Shares Outstanding
- N/A
- 52-Week Range
- $26.61 - $39.90
FBTCX Mutual Fund News
Insmed Advances Early-Stage INS1033 Study as Investors Await Safety Data
Insmed ($INSM) announced an update on their ongoing clinical study. Study Overview: Insmed’s NCT07765706 study is officially titled “A Phase 1, Randomized, Double-blind, Placebo-controlled, 2-Part Study to Assess Safety, Tolerability
FBTCX Mutual Fund Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| ABBVAbbvie | 14.71% |
| GILDGilead Sciences | 5.70% |
| SYRESpyre Therapeutics, Inc | 3.83% |
| ALNYAlnylam Pharmaceuticals | 3.62% |
| DNTHDianthus Therapeutics, Inc. | 3.55% |
| COGTCogent Biosciences, Inc. | 3.25% |
| ORKAOruka Therapeutics, Inc. | 3.24% |
| INSMInsmed | 3.05% |
| RVMDRevolution Medicines, Inc. | 3.00% |
| ARGXArgenx | 3.00% |
| Total | 46.95% |
Recently Viewed
No data currently available






